{
  "protocolSection.identificationModule.nctId": "NCT06047548",
  "protocolSection.identificationModule.orgStudyIdInfo.id": "18720",
  "protocolSection.identificationModule.secondaryIdInfos[0].id": "I8F-MC-GPIQ",
  "protocolSection.identificationModule.secondaryIdInfos[0].type": "OTHER",
  "protocolSection.identificationModule.secondaryIdInfos[0].domain": "Eli Lilly and Company",
  "protocolSection.identificationModule.organization.fullName": "Eli Lilly and Company",
  "protocolSection.identificationModule.organization.class": "INDUSTRY",
  "protocolSection.identificationModule.briefTitle": "A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities",
  "protocolSection.identificationModule.officialTitle": "A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Once Weekly 5 mg and/or Maximum Tolerated Dose Versus Placebo for Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (SURMOUNT-MAINTAIN)",
  "protocolSection.statusModule.statusVerifiedDate": "2025-04",
  "protocolSection.statusModule.overallStatus": "ACTIVE_NOT_RECRUITING",
  "protocolSection.statusModule.expandedAccessInfo.hasExpandedAccess": false,
  "protocolSection.statusModule.startDateStruct.date": "2023-09-20",
  "protocolSection.statusModule.startDateStruct.type": "ACTUAL",
  "protocolSection.statusModule.primaryCompletionDateStruct.date": "2026-05",
  "protocolSection.statusModule.primaryCompletionDateStruct.type": "ESTIMATED",
  "protocolSection.statusModule.completionDateStruct.date": "2026-05",
  "protocolSection.statusModule.completionDateStruct.type": "ESTIMATED",
  "protocolSection.statusModule.studyFirstSubmitDate": "2023-09-14",
  "protocolSection.statusModule.studyFirstSubmitQcDate": "2023-09-14",
  "protocolSection.statusModule.studyFirstPostDateStruct.date": "2023-09-21",
  "protocolSection.statusModule.studyFirstPostDateStruct.type": "ACTUAL",
  "protocolSection.statusModule.lastUpdateSubmitDate": "2025-04-17",
  "protocolSection.statusModule.lastUpdatePostDateStruct.date": "2025-04-18",
  "protocolSection.statusModule.lastUpdatePostDateStruct.type": "ACTUAL",
  "protocolSection.sponsorCollaboratorsModule.responsibleParty.type": "SPONSOR",
  "protocolSection.sponsorCollaboratorsModule.leadSponsor.name": "Eli Lilly and Company",
  "protocolSection.sponsorCollaboratorsModule.leadSponsor.class": "INDUSTRY",
  "protocolSection.oversightModule.oversightHasDmc": false,
  "protocolSection.oversightModule.isFdaRegulatedDrug": true,
  "protocolSection.oversightModule.isFdaRegulatedDevice": false,
  "protocolSection.descriptionModule.briefSummary": "The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction.",
  "protocolSection.descriptionModule.detailedDescription": "All enrolled participants will complete a 60-week open-label Weight-Loss Period on tirzepatide maximum tolerated dose (MTD) and upon meeting randomization criteria will enter a 52-week double-blinded Weight Maintenance Period to be assigned to either tirzepatide 5 mg, tirzepatide MTD or placebo.",
  "protocolSection.conditionsModule.conditions[0]": "Overweight",
  "protocolSection.conditionsModule.conditions[1]": "Obesity",
  "protocolSection.designModule.studyType": "INTERVENTIONAL",
  "protocolSection.designModule.phases[0]": "PHASE3",
  "protocolSection.designModule.designInfo.allocation": "RANDOMIZED",
  "protocolSection.designModule.designInfo.interventionModel": "PARALLEL",
  "protocolSection.designModule.designInfo.interventionModelDescription": "3b",
  "protocolSection.designModule.designInfo.primaryPurpose": "TREATMENT",
  "protocolSection.designModule.designInfo.maskingInfo.masking": "DOUBLE",
  "protocolSection.designModule.designInfo.maskingInfo.whoMasked[0]": "PARTICIPANT",
  "protocolSection.designModule.designInfo.maskingInfo.whoMasked[1]": "INVESTIGATOR",
  "protocolSection.designModule.enrollmentInfo.count": 400,
  "protocolSection.designModule.enrollmentInfo.type": "ESTIMATED",
  "protocolSection.armsInterventionsModule.armGroups[0].label": "Tirzepatide 5 milligram (mg)",
  "protocolSection.armsInterventionsModule.armGroups[0].type": "EXPERIMENTAL",
  "protocolSection.armsInterventionsModule.armGroups[0].description": "Participants will receive tirzepatide subcutaneously (SC).",
  "protocolSection.armsInterventionsModule.armGroups[0].interventionNames[0]": "Drug: Tirzepatide",
  "protocolSection.armsInterventionsModule.armGroups[1].label": "Tirzepatide Maximum Tolerated Dose",
  "protocolSection.armsInterventionsModule.armGroups[1].type": "EXPERIMENTAL",
  "protocolSection.armsInterventionsModule.armGroups[1].description": "Participants will receive tirzepatide SC.",
  "protocolSection.armsInterventionsModule.armGroups[1].interventionNames[0]": "Drug: Tirzepatide",
  "protocolSection.armsInterventionsModule.armGroups[2].label": "Placebo",
  "protocolSection.armsInterventionsModule.armGroups[2].type": "PLACEBO_COMPARATOR",
  "protocolSection.armsInterventionsModule.armGroups[2].description": "Participants will receive placebo.",
  "protocolSection.armsInterventionsModule.armGroups[2].interventionNames[0]": "Drug: Placebo",
  "protocolSection.armsInterventionsModule.interventions[0].type": "DRUG",
  "protocolSection.armsInterventionsModule.interventions[0].name": "Tirzepatide",
  "protocolSection.armsInterventionsModule.interventions[0].description": "Administered SC",
  "protocolSection.armsInterventionsModule.interventions[0].armGroupLabels[0]": "Tirzepatide 5 milligram (mg)",
  "protocolSection.armsInterventionsModule.interventions[0].armGroupLabels[1]": "Tirzepatide Maximum Tolerated Dose",
  "protocolSection.armsInterventionsModule.interventions[0].otherNames[0]": "LY3298176",
  "protocolSection.armsInterventionsModule.interventions[1].type": "DRUG",
  "protocolSection.armsInterventionsModule.interventions[1].name": "Placebo",
  "protocolSection.armsInterventionsModule.interventions[1].description": "Administered SC",
  "protocolSection.armsInterventionsModule.interventions[1].armGroupLabels[0]": "Placebo",
  "protocolSection.outcomesModule.primaryOutcomes[0].measure": "Percent Maintenance of Body Weight (BW) Reduction Achieved during the 60-Week Weight Loss Period",
  "protocolSection.outcomesModule.primaryOutcomes[0].description": "Mean percent maintenance of BW reduction achieved during the 60-Week weight loss period will be measured in participants who have reached a BW plateau.",
  "protocolSection.outcomesModule.primaryOutcomes[0].timeFrame": "Week 112",
  "protocolSection.outcomesModule.secondaryOutcomes[0].measure": "Number of Participants with an Assessment of (yes/no) of Maintaining ≥80% of the BW Reduction Achieved During the 60-week Weight-Loss Period",
  "protocolSection.outcomesModule.secondaryOutcomes[0].description": "Assessment of (yes/no) of maintaining ≥80% of the BW reduction achieved during the 60-week weight loss period will be measured in participants who have reached a BW plateau.",
  "protocolSection.outcomesModule.secondaryOutcomes[0].timeFrame": "Week 112",
  "protocolSection.outcomesModule.secondaryOutcomes[1].measure": "Number of Participants with an Assessment of (yes/no) of Maintaining ≥ 15% BW Reduction for Participants Who Have Already Lost ≥15% BW at Randomization",
  "protocolSection.outcomesModule.secondaryOutcomes[1].description": "Assessment of (yes/no) of maintaining ≥15% BW reduction for participants who have already lost ≥15% BW at randomization will be measured in participants who have reached a BW plateau.",
  "protocolSection.outcomesModule.secondaryOutcomes[1].timeFrame": "Week 112",
  "protocolSection.outcomesModule.secondaryOutcomes[2].measure": "Percent Change from Baseline in Body Weight",
  "protocolSection.outcomesModule.secondaryOutcomes[2].timeFrame": "Baseline (Week 0), Week 112",
  "protocolSection.outcomesModule.secondaryOutcomes[3].measure": "Change from Randomization in Body Weight",
  "protocolSection.outcomesModule.secondaryOutcomes[3].timeFrame": "Week 60, Week 112",
  "protocolSection.outcomesModule.secondaryOutcomes[4].measure": "Percent Change from Randomization in Body Weight",
  "protocolSection.outcomesModule.secondaryOutcomes[4].timeFrame": "Week 60, Week 112",
  "protocolSection.outcomesModule.secondaryOutcomes[5].measure": "Change from Randomization in Waist Circumference",
  "protocolSection.outcomesModule.secondaryOutcomes[5].timeFrame": "Week 60, Week 112",
  "protocolSection.outcomesModule.secondaryOutcomes[6].measure": "Percent Maintenance of BW Reduction Achieved During the 60-week Weight-Loss Period",
  "protocolSection.outcomesModule.secondaryOutcomes[6].timeFrame": "Week 84",
  "protocolSection.eligibilityModule.eligibilityCriteria": "Inclusion Criteria:\n\n* Have a Body Mass Index (BMI) of ≥30 kilogram/square meter (kg/m²) or ≥27 kg/m² and previously diagnosed with at least 1 of the following weight related comorbidities:\n\n  * Hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease\n* Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight (BW)\n\nExclusion Criteria:\n\n* Have Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D), a history of ketoacidosis, or hyperosmolar state or coma.\n* Have a self-reported change in BW\\>5 kilogram (kg) within 3 months prior to screening\n* Have a prior or planned surgical treatment for obesity, excluding liposuction or abdominoplasty if performed \\>1 year prior to screening.\n* Have a history of chronic or acute pancreatitis\n* Have any of the following cardiovascular conditions within 3 months prior to week 0.\n\n  * Acute myocardial infarction, cerebrovascular accident (stroke), unstable angina, and hospitalization due to congestive heart failure (CHF)\n  * family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)\n* History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years\n* Any lifetime history of a suicide attempt",
  "protocolSection.eligibilityModule.healthyVolunteers": false,
  "protocolSection.eligibilityModule.sex": "ALL",
  "protocolSection.eligibilityModule.minimumAge": "18 Years",
  "protocolSection.eligibilityModule.stdAges[0]": "ADULT",
  "protocolSection.eligibilityModule.stdAges[1]": "OLDER_ADULT",
  "protocolSection.contactsLocationsModule.overallOfficials[0].name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",
  "protocolSection.contactsLocationsModule.overallOfficials[0].affiliation": "Eli Lilly and Company",
  "protocolSection.contactsLocationsModule.overallOfficials[0].role": "STUDY_DIRECTOR",
  "protocolSection.contactsLocationsModule.locations[0].facility": "Cahaba Research - Pelham",
  "protocolSection.contactsLocationsModule.locations[0].city": "Pelham",
  "protocolSection.contactsLocationsModule.locations[0].state": "Alabama",
  "protocolSection.contactsLocationsModule.locations[0].zip": "35124",
  "protocolSection.contactsLocationsModule.locations[0].country": "United States",
  "protocolSection.contactsLocationsModule.locations[0].geoPoint.lat": 33.28567,
  "protocolSection.contactsLocationsModule.locations[0].geoPoint.lon": -86.80999,
  "protocolSection.contactsLocationsModule.locations[1].facility": "Velocity Clinical Research, Westlake",
  "protocolSection.contactsLocationsModule.locations[1].city": "Los Angeles",
  "protocolSection.contactsLocationsModule.locations[1].state": "California",
  "protocolSection.contactsLocationsModule.locations[1].zip": "90057",
  "protocolSection.contactsLocationsModule.locations[1].country": "United States",
  "protocolSection.contactsLocationsModule.locations[1].geoPoint.lat": 34.05223,
  "protocolSection.contactsLocationsModule.locations[1].geoPoint.lon": -118.24368,
  "protocolSection.contactsLocationsModule.locations[2].facility": "Southern California Dermatology, Inc.",
  "protocolSection.contactsLocationsModule.locations[2].city": "Santa Ana",
  "protocolSection.contactsLocationsModule.locations[2].state": "California",
  "protocolSection.contactsLocationsModule.locations[2].zip": "92701",
  "protocolSection.contactsLocationsModule.locations[2].country": "United States",
  "protocolSection.contactsLocationsModule.locations[2].geoPoint.lat": 33.74557,
  "protocolSection.contactsLocationsModule.locations[2].geoPoint.lon": -117.86783,
  "protocolSection.contactsLocationsModule.locations[3].facility": "Encompass Clinical Research",
  "protocolSection.contactsLocationsModule.locations[3].city": "Spring Valley",
  "protocolSection.contactsLocationsModule.locations[3].state": "California",
  "protocolSection.contactsLocationsModule.locations[3].zip": "91978",
  "protocolSection.contactsLocationsModule.locations[3].country": "United States",
  "protocolSection.contactsLocationsModule.locations[3].geoPoint.lat": 32.74477,
  "protocolSection.contactsLocationsModule.locations[3].geoPoint.lon": -116.99892,
  "protocolSection.contactsLocationsModule.locations[4].facility": "New Horizon Research Center",
  "protocolSection.contactsLocationsModule.locations[4].city": "Miami",
  "protocolSection.contactsLocationsModule.locations[4].state": "Florida",
  "protocolSection.contactsLocationsModule.locations[4].zip": "33165",
  "protocolSection.contactsLocationsModule.locations[4].country": "United States",
  "protocolSection.contactsLocationsModule.locations[4].geoPoint.lat": 25.77427,
  "protocolSection.contactsLocationsModule.locations[4].geoPoint.lon": -80.19366,
  "protocolSection.contactsLocationsModule.locations[5].facility": "Oviedo Medical Research",
  "protocolSection.contactsLocationsModule.locations[5].city": "Oviedo",
  "protocolSection.contactsLocationsModule.locations[5].state": "Florida",
  "protocolSection.contactsLocationsModule.locations[5].zip": "32765",
  "protocolSection.contactsLocationsModule.locations[5].country": "United States",
  "protocolSection.contactsLocationsModule.locations[5].geoPoint.lat": 28.67,
  "protocolSection.contactsLocationsModule.locations[5].geoPoint.lon": -81.20812,
  "protocolSection.contactsLocationsModule.locations[6].facility": "Rophe Adult and Pediatric Medicine/SKYCRNG",
  "protocolSection.contactsLocationsModule.locations[6].city": "Union City",
  "protocolSection.contactsLocationsModule.locations[6].state": "Georgia",
  "protocolSection.contactsLocationsModule.locations[6].zip": "30291",
  "protocolSection.contactsLocationsModule.locations[6].country": "United States",
  "protocolSection.contactsLocationsModule.locations[6].geoPoint.lat": 33.58706,
  "protocolSection.contactsLocationsModule.locations[6].geoPoint.lon": -84.54243,
  "protocolSection.contactsLocationsModule.locations[7].facility": "East-West Medical Research Institute",
  "protocolSection.contactsLocationsModule.locations[7].city": "Honolulu",
  "protocolSection.contactsLocationsModule.locations[7].state": "Hawaii",
  "protocolSection.contactsLocationsModule.locations[7].zip": "96814",
  "protocolSection.contactsLocationsModule.locations[7].country": "United States",
  "protocolSection.contactsLocationsModule.locations[7].geoPoint.lat": 21.30694,
  "protocolSection.contactsLocationsModule.locations[7].geoPoint.lon": -157.85833,
  "protocolSection.contactsLocationsModule.locations[8].facility": "Rocky Mountain Clinical Research",
  "protocolSection.contactsLocationsModule.locations[8].city": "Idaho Falls",
  "protocolSection.contactsLocationsModule.locations[8].state": "Idaho",
  "protocolSection.contactsLocationsModule.locations[8].zip": "83404",
  "protocolSection.contactsLocationsModule.locations[8].country": "United States",
  "protocolSection.contactsLocationsModule.locations[8].geoPoint.lat": 43.46658,
  "protocolSection.contactsLocationsModule.locations[8].geoPoint.lon": -112.03414,
  "protocolSection.contactsLocationsModule.locations[9].facility": "Asha Clinical Research - Munster",
  "protocolSection.contactsLocationsModule.locations[9].city": "Hammond",
  "protocolSection.contactsLocationsModule.locations[9].state": "Indiana",
  "protocolSection.contactsLocationsModule.locations[9].zip": "46324",
  "protocolSection.contactsLocationsModule.locations[9].country": "United States",
  "protocolSection.contactsLocationsModule.locations[9].geoPoint.lat": 41.58337,
  "protocolSection.contactsLocationsModule.locations[9].geoPoint.lon": -87.50004,
  "protocolSection.contactsLocationsModule.locations[10].facility": "Iowa Diabetes and Endocrinology Research Center",
  "protocolSection.contactsLocationsModule.locations[10].city": "West Des Moines",
  "protocolSection.contactsLocationsModule.locations[10].state": "Iowa",
  "protocolSection.contactsLocationsModule.locations[10].zip": "50265",
  "protocolSection.contactsLocationsModule.locations[10].country": "United States",
  "protocolSection.contactsLocationsModule.locations[10].geoPoint.lat": 41.57721,
  "protocolSection.contactsLocationsModule.locations[10].geoPoint.lon": -93.71133,
  "protocolSection.contactsLocationsModule.locations[11].facility": "L-MARC Research Center",
  "protocolSection.contactsLocationsModule.locations[11].city": "Louisville",
  "protocolSection.contactsLocationsModule.locations[11].state": "Kentucky",
  "protocolSection.contactsLocationsModule.locations[11].zip": "40213",
  "protocolSection.contactsLocationsModule.locations[11].country": "United States",
  "protocolSection.contactsLocationsModule.locations[11].geoPoint.lat": 38.25424,
  "protocolSection.contactsLocationsModule.locations[11].geoPoint.lon": -85.75941,
  "protocolSection.contactsLocationsModule.locations[12].facility": "Prime Health and Wellness/SKYCRNG",
  "protocolSection.contactsLocationsModule.locations[12].city": "Fayette",
  "protocolSection.contactsLocationsModule.locations[12].state": "Mississippi",
  "protocolSection.contactsLocationsModule.locations[12].zip": "39069",
  "protocolSection.contactsLocationsModule.locations[12].country": "United States",
  "protocolSection.contactsLocationsModule.locations[12].geoPoint.lat": 31.71155,
  "protocolSection.contactsLocationsModule.locations[12].geoPoint.lon": -91.06066,
  "protocolSection.contactsLocationsModule.locations[13].facility": "Alliance for Multispecialty Research, LLC",
  "protocolSection.contactsLocationsModule.locations[13].city": "Norman",
  "protocolSection.contactsLocationsModule.locations[13].state": "Oklahoma",
  "protocolSection.contactsLocationsModule.locations[13].zip": "73069",
  "protocolSection.contactsLocationsModule.locations[13].country": "United States",
  "protocolSection.contactsLocationsModule.locations[13].geoPoint.lat": 35.22257,
  "protocolSection.contactsLocationsModule.locations[13].geoPoint.lon": -97.43948,
  "protocolSection.contactsLocationsModule.locations[14].facility": "WR-Clinsearch, LLC",
  "protocolSection.contactsLocationsModule.locations[14].city": "Chattanooga",
  "protocolSection.contactsLocationsModule.locations[14].state": "Tennessee",
  "protocolSection.contactsLocationsModule.locations[14].zip": "37397",
  "protocolSection.contactsLocationsModule.locations[14].country": "United States",
  "protocolSection.contactsLocationsModule.locations[14].geoPoint.lat": 35.04563,
  "protocolSection.contactsLocationsModule.locations[14].geoPoint.lon": -85.30968,
  "protocolSection.contactsLocationsModule.locations[15].facility": "The University of Texas Health Science Center at Houston",
  "protocolSection.contactsLocationsModule.locations[15].city": "Bellaire",
  "protocolSection.contactsLocationsModule.locations[15].state": "Texas",
  "protocolSection.contactsLocationsModule.locations[15].zip": "77401",
  "protocolSection.contactsLocationsModule.locations[15].country": "United States",
  "protocolSection.contactsLocationsModule.locations[15].geoPoint.lat": 29.70579,
  "protocolSection.contactsLocationsModule.locations[15].geoPoint.lon": -95.45883,
  "protocolSection.contactsLocationsModule.locations[16].facility": "Velocity Clinical Research, Dallas",
  "protocolSection.contactsLocationsModule.locations[16].city": "Dallas",
  "protocolSection.contactsLocationsModule.locations[16].state": "Texas",
  "protocolSection.contactsLocationsModule.locations[16].zip": "75230",
  "protocolSection.contactsLocationsModule.locations[16].country": "United States",
  "protocolSection.contactsLocationsModule.locations[16].geoPoint.lat": 32.78306,
  "protocolSection.contactsLocationsModule.locations[16].geoPoint.lon": -96.80667,
  "protocolSection.contactsLocationsModule.locations[17].facility": "Southern Endocrinology Associates",
  "protocolSection.contactsLocationsModule.locations[17].city": "Mesquite",
  "protocolSection.contactsLocationsModule.locations[17].state": "Texas",
  "protocolSection.contactsLocationsModule.locations[17].zip": "75149",
  "protocolSection.contactsLocationsModule.locations[17].country": "United States",
  "protocolSection.contactsLocationsModule.locations[17].geoPoint.lat": 32.7668,
  "protocolSection.contactsLocationsModule.locations[17].geoPoint.lon": -96.59916,
  "protocolSection.contactsLocationsModule.locations[18].facility": "Pinnacle Clinical Research",
  "protocolSection.contactsLocationsModule.locations[18].city": "San Antonio",
  "protocolSection.contactsLocationsModule.locations[18].state": "Texas",
  "protocolSection.contactsLocationsModule.locations[18].zip": "78229",
  "protocolSection.contactsLocationsModule.locations[18].country": "United States",
  "protocolSection.contactsLocationsModule.locations[18].geoPoint.lat": 29.42412,
  "protocolSection.contactsLocationsModule.locations[18].geoPoint.lon": -98.49363,
  "protocolSection.contactsLocationsModule.locations[19].facility": "Consano Clinical Research, LLC",
  "protocolSection.contactsLocationsModule.locations[19].city": "Shavano Park",
  "protocolSection.contactsLocationsModule.locations[19].state": "Texas",
  "protocolSection.contactsLocationsModule.locations[19].zip": "78231",
  "protocolSection.contactsLocationsModule.locations[19].country": "United States",
  "protocolSection.contactsLocationsModule.locations[19].geoPoint.lat": 29.58495,
  "protocolSection.contactsLocationsModule.locations[19].geoPoint.lon": -98.55252,
  "protocolSection.referencesModule.seeAlsoLinks[0].label": "A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities",
  "protocolSection.referencesModule.seeAlsoLinks[0].url": "https://trials.lilly.com/en-US/trial/424336",
  "protocolSection.ipdSharingStatementModule.ipdSharing": "YES",
  "protocolSection.ipdSharingStatementModule.description": "Anonymized individual participant level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.",
  "protocolSection.ipdSharingStatementModule.infoTypes[0]": "STUDY_PROTOCOL",
  "protocolSection.ipdSharingStatementModule.infoTypes[1]": "SAP",
  "protocolSection.ipdSharingStatementModule.infoTypes[2]": "CSR",
  "protocolSection.ipdSharingStatementModule.timeFrame": "Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.",
  "protocolSection.ipdSharingStatementModule.accessCriteria": "A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.",
  "protocolSection.ipdSharingStatementModule.url": "http://vivli.org/",
  "derivedSection.miscInfoModule.versionHolder": "2025-07-01",
  "derivedSection.conditionBrowseModule.meshes[0].id": "D009765",
  "derivedSection.conditionBrowseModule.meshes[0].term": "Obesity",
  "derivedSection.conditionBrowseModule.meshes[1].id": "D050177",
  "derivedSection.conditionBrowseModule.meshes[1].term": "Overweight",
  "derivedSection.conditionBrowseModule.meshes[2].id": "D001835",
  "derivedSection.conditionBrowseModule.meshes[2].term": "Body Weight",
  "derivedSection.conditionBrowseModule.meshes[3].id": "D015431",
  "derivedSection.conditionBrowseModule.meshes[3].term": "Weight Loss",
  "derivedSection.conditionBrowseModule.ancestors[0].id": "D044343",
  "derivedSection.conditionBrowseModule.ancestors[0].term": "Overnutrition",
  "derivedSection.conditionBrowseModule.ancestors[1].id": "D009748",
  "derivedSection.conditionBrowseModule.ancestors[1].term": "Nutrition Disorders",
  "derivedSection.conditionBrowseModule.ancestors[2].id": "D001836",
  "derivedSection.conditionBrowseModule.ancestors[2].term": "Body Weight Changes",
  "derivedSection.conditionBrowseModule.browseLeaves[0].id": "M5114",
  "derivedSection.conditionBrowseModule.browseLeaves[0].name": "Body Weight",
  "derivedSection.conditionBrowseModule.browseLeaves[0].asFound": "Body Weight",
  "derivedSection.conditionBrowseModule.browseLeaves[0].relevance": "HIGH",
  "derivedSection.conditionBrowseModule.browseLeaves[1].id": "M26186",
  "derivedSection.conditionBrowseModule.browseLeaves[1].name": "Overweight",
  "derivedSection.conditionBrowseModule.browseLeaves[1].asFound": "Overweight",
  "derivedSection.conditionBrowseModule.browseLeaves[1].relevance": "HIGH",
  "derivedSection.conditionBrowseModule.browseLeaves[2].id": "M12701",
  "derivedSection.conditionBrowseModule.browseLeaves[2].name": "Obesity",
  "derivedSection.conditionBrowseModule.browseLeaves[2].asFound": "Obesity",
  "derivedSection.conditionBrowseModule.browseLeaves[2].relevance": "HIGH",
  "derivedSection.conditionBrowseModule.browseLeaves[3].id": "M18102",
  "derivedSection.conditionBrowseModule.browseLeaves[3].name": "Weight Loss",
  "derivedSection.conditionBrowseModule.browseLeaves[3].asFound": "Weight Reduction",
  "derivedSection.conditionBrowseModule.browseLeaves[3].relevance": "HIGH",
  "derivedSection.conditionBrowseModule.browseLeaves[4].id": "M25307",
  "derivedSection.conditionBrowseModule.browseLeaves[4].name": "Overnutrition",
  "derivedSection.conditionBrowseModule.browseLeaves[4].relevance": "LOW",
  "derivedSection.conditionBrowseModule.browseLeaves[5].id": "M12684",
  "derivedSection.conditionBrowseModule.browseLeaves[5].name": "Nutrition Disorders",
  "derivedSection.conditionBrowseModule.browseLeaves[5].relevance": "LOW",
  "derivedSection.conditionBrowseModule.browseLeaves[6].id": "M5115",
  "derivedSection.conditionBrowseModule.browseLeaves[6].name": "Body Weight Changes",
  "derivedSection.conditionBrowseModule.browseLeaves[6].relevance": "LOW",
  "derivedSection.conditionBrowseModule.browseBranches[0].abbrev": "BC23",
  "derivedSection.conditionBrowseModule.browseBranches[0].name": "Symptoms and General Pathology",
  "derivedSection.conditionBrowseModule.browseBranches[1].abbrev": "All",
  "derivedSection.conditionBrowseModule.browseBranches[1].name": "All Conditions",
  "derivedSection.conditionBrowseModule.browseBranches[2].abbrev": "BC18",
  "derivedSection.conditionBrowseModule.browseBranches[2].name": "Nutritional and Metabolic Diseases",
  "derivedSection.interventionBrowseModule.meshes[0].id": "C000629749",
  "derivedSection.interventionBrowseModule.meshes[0].term": "Tirzepatide",
  "derivedSection.interventionBrowseModule.ancestors[0].id": "D054795",
  "derivedSection.interventionBrowseModule.ancestors[0].term": "Incretins",
  "derivedSection.interventionBrowseModule.ancestors[1].id": "D006728",
  "derivedSection.interventionBrowseModule.ancestors[1].term": "Hormones",
  "derivedSection.interventionBrowseModule.ancestors[2].id": "D006730",
  "derivedSection.interventionBrowseModule.ancestors[2].term": "Hormones, Hormone Substitutes, and Hormone Antagonists",
  "derivedSection.interventionBrowseModule.ancestors[3].id": "D045505",
  "derivedSection.interventionBrowseModule.ancestors[3].term": "Physiological Effects of Drugs",
  "derivedSection.interventionBrowseModule.browseLeaves[0].id": "M4854",
  "derivedSection.interventionBrowseModule.browseLeaves[0].name": "Benzocaine",
  "derivedSection.interventionBrowseModule.browseLeaves[0].relevance": "LOW",
  "derivedSection.interventionBrowseModule.browseLeaves[1].id": "M204206",
  "derivedSection.interventionBrowseModule.browseLeaves[1].name": "Tirzepatide",
  "derivedSection.interventionBrowseModule.browseLeaves[1].asFound": "De novo",
  "derivedSection.interventionBrowseModule.browseLeaves[1].relevance": "HIGH",
  "derivedSection.interventionBrowseModule.browseLeaves[2].id": "M27905",
  "derivedSection.interventionBrowseModule.browseLeaves[2].name": "Incretins",
  "derivedSection.interventionBrowseModule.browseLeaves[2].relevance": "LOW",
  "derivedSection.interventionBrowseModule.browseLeaves[3].id": "M9789",
  "derivedSection.interventionBrowseModule.browseLeaves[3].name": "Hormones",
  "derivedSection.interventionBrowseModule.browseLeaves[3].relevance": "LOW",
  "derivedSection.interventionBrowseModule.browseLeaves[4].id": "M9788",
  "derivedSection.interventionBrowseModule.browseLeaves[4].name": "Hormone Antagonists",
  "derivedSection.interventionBrowseModule.browseLeaves[4].relevance": "LOW",
  "derivedSection.interventionBrowseModule.browseLeaves[5].id": "T433",
  "derivedSection.interventionBrowseModule.browseLeaves[5].name": "Tannic Acid",
  "derivedSection.interventionBrowseModule.browseLeaves[5].relevance": "LOW",
  "derivedSection.interventionBrowseModule.browseBranches[0].abbrev": "CNSDep",
  "derivedSection.interventionBrowseModule.browseBranches[0].name": "Central Nervous System Depressants",
  "derivedSection.interventionBrowseModule.browseBranches[1].abbrev": "All",
  "derivedSection.interventionBrowseModule.browseBranches[1].name": "All Drugs and Chemicals",
  "derivedSection.interventionBrowseModule.browseBranches[2].abbrev": "Ot",
  "derivedSection.interventionBrowseModule.browseBranches[2].name": "Other Dietary Supplements",
  "hasResults": false
}